Drug interactions are usually seen in clinical practice and the interactions are evaluated usually in animal models. We studied the influence of Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Glimepiride in normal and diabetic rats. In this study Pharmacokinetics of Glimepiride (2mg/kg/ p.o.) was studied in adult healthy Spargue-Dawly rats (n=6). In first phase, the Pharmacokinetics of Glimepiride (2mg/kg/p.o.) was studied. After a washout period of one week the animals were used for second phase studies and were administered with Lansoprazole (30 mg/kg/p.o.) and Glimepiride (2mg/kg/p.o.) 30 minutes later. In the third phase, the animals were administered with Lansoprazole (30 mg/kg/p.o.) for 7 consecutive days to the post second phase. On the 8th day of post second phase and 30 minutes after the Lansoprazole (30 mg/kg) administration, Glimepiride (2mg/kg/p.o.) was administered. And pharmacodynamic study was evaluated in single and multiple studies of both diabetic and normal rats. In all the blood samples were collected from the orbital sinuses at time intervals of 0, 1, 2, 4, 8, 12, 24 hours and the drug concentrations were estimated using HPLC and glucose levels estimated using GOD-POD Method and the PK-PD parameters were calculated. Increase in AUC, Cmax indicates the improved bioavailability of Glimepiride in presence of Lansoprazole. And statistically significant difference in glucose levels was observed in single and multiple studies of both diabetic and normal rats.
